Novavax COVID-19 Vaccine Nuvaxovid(TM) Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

– In Australia, Nuvaxovid(TM) is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history

Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of Nuvaxovid(TM) (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over.

“Today’s provisional registration for Nuvaxovid as a booster in Australia is an important step in ensuring broad global access to diversified vaccine options,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “As COVID-19 continues to persist and evolve, we are pleased to be able to offer the first protein-based COVID-19 vaccine registered for use as both a primary series and now booster regardless of previous vaccine history.”

The provisional registration was based on data from Novavax’ Phase 2 trial ( https://c212.net/c/link/?t=0&l=en&o=3564758-1&h=2627944671&u=https%3A%2F%2Fir.novavax.com%2F2021-12-22-Novavax-Announces-Initial-Omicron-Cross-Reactivity-Data-from-COVID-19-Vaccine-Booster-and-Adolescent-Studies&a=Phase+2+trial ) conducted in Australia, from a separate Phase 2 trial conducted in South Africa, and from the UK-sponsored COV-BOOST trial. As part of the Phase 2 trials, a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six months after their primary two-dose vaccination series of Nuvaxovid. The third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials. In the COV-BOOST trial, Nuvaxovid induced a robust antibody response when used as a heterologous third booster dose.

In the Novavax-sponsored trials, following the booster, local and systemic reactions were generally short-lived with a median duration of approximately two days. The incidence of Grade 3 or higher events remained relatively low. Safety reporting of reactogenicity events showed an increasing incidence across all three doses of Nuvaxovid, reflecting the increased immunogenicity seen with a third dose. Medically attended adverse events, potentially immune-mediated medical conditions, and severe adverse events occurred infrequently following the booster dose and were balanced between vaccine and placebo groups.

The TGA granted provisional registration in January 2022 ( https://c212.net/c/link/?t=0&l=en&o=3564758-1&h=1536266732&u=https%3A%2F%2Fir.novavax.com%2F2022-01-19-Australia-Therapeutic-Goods-Administration-TGA-Grants-Provisional-Registration-for-Novavax-COVID-19-Vaccine&a=January+2022 ) for use of Nuvaxovid in individuals aged 18 and over. Novavax filed for expanded provisional registration in Australia for use in adolescents aged 12 through 17 in May 2022 ( https://c212.net/c/link/?t=0&l=en&o=3564758-1&h=3055502229&u=https%3A%2F%2Fir.novavax.com%2FNovavax-Submits-Variations-to-Expand-Australian-and-New-Zealand-Provisional-Approval-of-Nuvaxovid-TM-COVID-19-Vaccine-to-Adolescents-aged-12-Through-17-Years&a=May+2022 ).

Novavax’ sponsor in Australia is Biocelect Pty. Ltd.

Authorization in the U.S.
The Novavax COVID-19 vaccine (NVX-CoV2373) has not yet been authorized for use in the U.S. and the trade name Nuvaxovid(TM) has not yet been approved by the U.S. Food and Drug Administration.

Important Safety Information

— Nuvaxovid is contraindicated in persons who have a hypersensitivity
to the active substance, or to any of the excipients.
— Events of anaphylaxis have been reported with administration of
COVID-19 vaccines. Appropriate medical treatment and supervision should
be available in case of an anaphylactic reaction following the
administration of the vaccine. Close observation for at least 15 minutes
is recommended and a second dose of the vaccine should not be given to
those who have experienced anaphylaxis to the first dose of Nuvaxovid.
— Anxiety-related reactions, including vasovagal reactions (syncope),
hyperventilation, or stress‐related reactions may occur in
association with vaccination as a psychogenic response to the needle
injection. It is important that precautions are in place to avoid
injury from fainting.
— Vaccination should be postponed in individuals suffering from an acute
severe febrile illness or acute infection. The presence of a minor
infection and/or low-grade fever should not delay vaccination.
— Nuvaxovid should be given with caution in individuals receiving
anticoagulant therapy or those with thrombocytopenia or any coagulation
disorder (such as haemophilia) because bleeding or bruising may occur
following an intramuscular administration in these individuals.
— The efficacy of Nuvaxovid may be lower in immunosuppressed individuals.
— Administration of Nuvaxovid in pregnancy should only be considered when
the potential benefits outweigh any potential risks for the mother
and foetus.
— The effects with Nuvaxovid may temporarily affect the ability to drive
or use machines.
— Individuals may not be fully protected until seven days after their
second dose. As with all vaccines, vaccination with Nuvaxovid may not
protect all vaccine recipients.
— The most common adverse reactions observed during clinical studies were
headache, nausea or vomiting, myalgia, arthralgia, injection site
tenderness/pain, fatigue, and malaise.

For more information on Nuvaxovid, including the Australian approved Product Information, Australian approved Consumer Medicines Information and Important Safety Information, or to request additional information please visit the following websites:

— Australian TGA website ( https://c212.net/c/link/?t=0&l=en&o=3564758-1&h=2626566454&u=https%3A%2F%2Fwww.tga.gov.au%2Fcovid-19-vaccine-provisional-registrations&a=Australian+TGA+website )
— Novavax global authorization website ( https://c212.net/c/link/?t=0&l=en&o=3564758-1&h=598718145&u=https%3A%2F%2Fwww.novavaxcovidvaccine.com%2F&a=global+authorization+website )

About NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax’ patented saponin-based Matrix-M(TM) adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

The Novavax COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2 degrees – 8 degrees Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.

Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax’ manufacturing partnership with Serum Institute of India, the world’s largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax’ global supply chain.

About the NVX-CoV2373 Phase 3 Trials
NVX-CoV2373 continues being evaluated in two pivotal Phase 3 trials.

PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations in the U.S. and Mexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI greater than 30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, NVX-CoV2373 achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in the New England Journal of Medicine (NEJM) ( https://c212.net/c/link/?t=0&l=en&o=3564758-1&h=1087536871&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D467849857%26u%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2116185%253Fquery%253Dfeatured_home%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine ).

The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of NVX-CoV2373 with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the U.S., compared with placebo. In the pediatric trial, NVX-CoV2373 achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S. Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.

PREVENT-19 is being conducted with support from the U.S. government, including the Department of Defense, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health at HHS. BARDA is providing up to $1.75 billion under a Department of Defense agreement (# MCDC2011-001).

Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in NEJM ( https://c212.net/c/link/?t=0&l=en&o=3564758-1&h=2740507576&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D3617137863%26u%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2107659%26a%3DNEJM&a=NEJM ).

About Matrix-M(TM) Adjuvant
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company’s COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide and will soon be under review in the U.S. for use in adults, adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. 

For more information, visit www.novavax.com and connect with us on LinkedIn ( https://www.linkedin.com/company/novavax/ ).

*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season. 

Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, a COVID-seasonal influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax’ upcoming FDA Advisory Committee meeting and including Novavax’ plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax’ global supply chain, additional worldwide authorizations of NVX-CoV2373 for adolescents, the evolving COVID-19 pandemic, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, including the potential for a booster dose of NVX-CoV2373 to provide protection against COVID-19 (including variants), the potential reach of NVX-CoV2373, the efficacy, safety and intended utilization of NVX-CoV2373, and expected administration of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Novavax’ Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:
Investors
Alex Delacroix | 240-268-2022
ir@novavax.com

Media
Ali Chartan | 240-720-7804
media@novavax.com

Logo – https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

SOURCE Novavax, Inc.